Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SLXN by emailGet an email when SLXN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SLXN, unsubscribe in one click. Privacy
📣 What SLXN Says Is Next
early 2027 · “SIL 204 Phase 2 / 3 in locally advanced pancreatic cancer received regulatory approval in Israel and Germany, initiated clinical trial July 2026 ; pre - IND meeting with FDA expected early 2027”
Company press release, Aug 10, 2026 · SEC filing
early 2027 · “The Company also plans to submit a Phase 2/3 clinical trial application in Germany by the end of this current quarter, with additional regulatory filings across the European Union planned in early 2027.”
Company press release, Mar 24, 2026 · SEC filing
in 2026 · “Additional regulatory submissions to Germany are planned for the first quarter of 2026, with additional European Union submissions expected later in 2026 and a U.S. IND submission anticipated in the second half of 2026.Our innovative dual-route strategy combines intratumoral delivery for primary tumors with systemic administration for metastases, addressing both components of this deadly disease.”
Company press release, Jan 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SLXN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLXN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.